<HashMap><database>EGA</database><scores/><additional><omics_type>Genomics</omics_type><technology_type>Illumina MiSeq, NextSeq 500, ILLUMINA</technology_type><study_type>Other</study_type><full_dataset_link>https://ega-archive.org/studies/EGAS00001003173</full_dataset_link><host>EGA</host><description>EGA study EGAS00001003173</description><dataset_title>Primary breast cancers and paired brain metastases</dataset_title><repository>EGA</repository><category>restricted</category><name_synonyms>mamma, the brain, mammary region, Breasts, suprasegmental structures, Lobe of mammary gland, Encephalon, Lobe of breast, mammary part of chest, Lactiferous gland, study., synganglion, suprasegmental levels of nervous system, Brustdruese, encephalon, glandula mammaria, breast</name_synonyms><description_synonyms>the brain, AU043776, CG34403, primary breast cancer, Macias-Flores Garcia-Cruz Rivera syndrome, malignant tumor of the breast, l(4)13, Plays, Materials, Polyarteritis Nodosa, Product, determination, Periarteritis Nodosa, Neoplasms, LEF/TCF-1, number, Benign Neoplasm, mammary neoplasm, Gene, DmelCG34403, Tumor, PDCE2, Malignant, presence, IA5, LEF-1, Intervention Study., protrusion, Mutations, Dmel_CG32005, "neoplasm of breast (disorder)" EXACT [SNOMEDCT_2005_07_31:126926005], PDC-E2, Roles, Pharmaceutical Product, resistance, LEF1/TCF, Concepts, hypertrichosis, "mammary tumor" EXACT [CSP2005:2016-0671], Classic Polyarteritis Nodosa, breast tumor, synganglion, primary, Toy, Drugs, malignant neoplasm of breast, TCF/LEF, Genetic, Playthings, Malignancy, c14_5346, Tcf-1, d-TCF, suprasegmental levels of nervous system, cTCF, Neoplasias, drugs, Cgh, Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex, Pyruvate dehydrogenase complex component E2, Puppets, medicine, malignant neoplasm, Pharmaceutical, TCF/LEF1, PBC cell, Role Concepts, familial primary biliary cirrhosis, Play, chimpanzees, Malignancies, Preparation, associated, mammary cancer, mammary tumor, polyarteritis, hypertrichosis congenital generalised X-linked, HTC2, Pan, PAN, Puppet, Pharmaceuticals, Cancer, Tumors, Products, suprasegmental structures, anatomical protrusion, "breast neoplasm" EXACT [MTH:120], chromosome Xq27.1 Interchromosomal insertion syndrome, Malignant Neoplasm, drug, PBC, Dmel_CG17964, C14orf32, 2310009E07Rik, "breast tumor" EXACT [NCI2004_11_17:C2910], Cistrons, encephalon, LEF/TCF, Dm Pan, Concept, congenital generalized, count in organism, Role Concept, MT, Benign, pan.dTCF, Playthings and Play, PERIANTHIA, chemical analysis, Role, chromosome Xq27.1 interchromosomal insertion syndrome, Neoplasm, Plaything, Genetic Materials, Pharmaceutic, Tcf, TCF, Tcf/LEF, Genetic Material, Lef1, periarteritis, Epistemology, primary cancer, LEF1, Pharmaceutic Preparations, F24J5.12, hCG, Encephalon, Classical Polyarteritis Nodosa, Panarteritis Nodosa, Toys, DTCF, DTcf, Benign Neoplasms, tcf, Cancers, MISS, CG17964, "mammary neoplasm" RELATED [], l(4)102ABb, malignant tumor, CG32005, F24J5_12, Malignant Neoplasms, Drug, M2 antigen complex 70 kDa subunit, metastatic, Preparations, congenital generalised, hypertrichosis congenital generalized X-linked, 2.3.1.12, spine, Material, Lef, biliary cirrhosis, cardinality, microarray, Cistron, assay, lef1, 70 kDa mitochondrial autoantigen of primary biliary cirrhosis, Pharmaceutical Products, Neoplasia, dTCF, dTcf, Pharmaceutical Preparation</description_synonyms></additional><is_claimable>false</is_claimable><name>Primary breast cancers and paired brain metastases sequencing study</name><description>Improving management of brain metastases (BM) from primary breast cancer (PBC) is a challenge in which targeted therapies play a promising role. However this approach is impaired by miss-knowledge of molecular patterns of the metastatic and drug-resistance processes.We performed a differential analysis of copy-number-alterations (CNAs) and mutations profiles by using pan-genomic array-CGH and targeted next-generation-sequencing of  494 cancer-associated genes, in a series of 14 pairs of matched PBC/BM and assessed if the observed genomic alterations may be used as a druggable agent in a clinical trial.</description><dates><updated>2018-08-24 09:51:00</updated></dates><accession>EGAS00001003173</accession><cross_references><TAXONOMY>9606</TAXONOMY><EGA>EGAD00001004309</EGA><EGA>EGAC00001000995</EGA></cross_references></HashMap>